Management of Statin-Associated Muscle Symptoms

Initial Diagnostic Workup

• The American College of Cardiology recommends ordering creatine kinase (CK) measurement, thyroid-stimulating hormone (TSH), and vitamin D levels in patients reporting muscle pain while on atorvastatin, to assess for muscle damage and rule out hypothyroidism and vitamin D deficiency 1, 3
• Renal function tests and hepatic function tests should be performed to identify multisystem disease that increases myopathy risk in patients on atorvastatin 1, 2
• Urinalysis for myoglobinuria is recommended if symptoms are severe or CK is markedly elevated in patients on atorvastatin 2, 3

Risk Factor Assessment

• Advanced age, especially over 80 years, significantly increases the risk of myopathy in patients on atorvastatin 1, 4
• Higher statin doses, such as 40mg of atorvastatin, increase the risk of myopathy compared to lower doses 1, 4
• Atorvastatin is more likely to cause myalgia at higher doses compared to pravastatin or rosuvastatin 4

Management Algorithm

• If CK is >10 times the upper limit of normal (ULN) with muscle symptoms, the American College of Cardiology recommends discontinuing atorvastatin immediately and evaluating for rhabdomyolysis 1, 3
• If CK is 3-10 times ULN with muscle symptoms, the American College of Cardiology recommends temporarily discontinuing atorvastatin and following symptoms and CK levels weekly until resolution 1, 3
• If CK is normal or mildly elevated (<3 times ULN) with muscle symptoms, the American College of Cardiology recommends temporarily discontinuing atorvastatin to establish causality and ruling out common causes such as recent exercise, strenuous work, hypothyroidism, and vitamin D deficiency 2, 3

Rechallenge Strategy

• The American College of Cardiology/American Heart Association guidelines recommend a rechallenge strategy after symptom resolution, including restarting atorvastatin at a lower dose or switching to a statin with lower myopathy risk such as pravastatin or rosuvastatin 2, 4
• If symptoms recur with rechallenge, non-statin alternatives such as ezetimibe or PCSK9 inhibitors may be considered 2, 4

Monitoring After Rechallenge

• The American College of Cardiology recommends monitoring muscle symptoms at baseline, 6-12 weeks after starting, and at each follow-up visit, as well as CK measurements whenever the patient reports muscle soreness, tenderness, or weakness 1, 4
• More frequent monitoring is recommended in high-risk elderly patients with frailty or multisystem disease 1, 4